TY - JOUR
TI - Association between body mass index and oocyte maturation in patients
triggered with GnRH agonist who are at high risk for severe ovarian
hyperstimulation syndrome: an observational cohort study
AU - Lainas, George T.
AU - Lainas, Tryfon G.
AU - Sfontouris, Ioannis A. and
AU - Venetis, Christos A.
AU - Bosdou, Julia K.
AU - Chatzimeletiou, Aikaterini
AU - and Grimbizis, Grigorios F.
AU - Tarlatzis, Basil C.
AU - Kolibianakis,
AU - Efstratios M.
JO - Reproductive Biomedicine Online
PY - 2020
VL - 40
TODO - 1
SP - 168-175
PB - Elsevier Sci Ltd, Exeter, United Kingdom
SN - 1472-6483, 1472-6491
TODO - 10.1016/j.rbmo.2019.10.006
TODO - BMI; Freeze all; GnRH agonist triggering; Oocyte maturation; Ovarian
hyperstimulation syndrome; Triptorelin
TODO - Research question: Is body-mass index (BMI) associated with oocyte
maturation in women at high risk for developing severe ovarian
hyperstimulation syndrome (OHSS) who are triggered with gonadotrophin
releasing hormone (GnRH) agonist?
Design: Prospective observational cohort study. A total of 113 patients
at high risk for severe OHSS (presence of at least 19 follicles >= 11
mm) pre-treated with gonadotrophin releasing hormone (GnRH) antagonists
and recombinant FSH were administered 0.2 mg triptorelin to trigger
final oocyte maturation. Patients were classified in two groups
depending on their BMI: BMI less than 25 kg/m(2) (n = 72) and BMI 25
kg/m(2) or over (n = 41). Baseline, ovarian stimulation and
embryological characteristics, as well as luteal-phase hormone profiles,
were compared in patients classified into the two BMI groups. The main
outcome measure was the number of mature oocytes.
Results: A significantly higher number of mature (metaphase II) oocytes
(19 [18-21] versus 16 [13-20], P = 0.029) was present in women with
BMI less than 25 kg/m(2) compared with those with BMI 25 kg/m(2) or
greater. The number of retrieved oocytes, the number of fertilized
oocytes, oocyte retrieval, maturation and fertilization rates were
similar in the two groups. A significantly higher dose of recombinant
FSH was required for patients with BMI 25 kg/m(2) or greater compared
with patients with BMI less than 25 kg/m(2) (1875 [1650-2150] IU
versus 1650 [1600-1750] IU, P = 0.003) and the two groups displayed
different luteal phase hormonal profiles.
Conclusions: Among women at high risk for developing severe OHSS who are
triggered with a standard dose (0.2 mg) of the GnRH agonist triptorelin,
women with BMI 25 kg/m(2) or greater had significantly fewer mature
oocytes, required a higher total dose of recombinant FSH compared with
women with BMI less than 25 kg/m(2).
ER -